Effects of nebivolol in obese African Americans with hypertension (NOAAH): markers of inflammation and obesity in response to exercise-induced stress

Abstract

We sought to determine whether the antihypertensive drug nebivolol has beneficial effects on vascular markers of inflammation and oxidation in obese African-American patients with hypertension when exposed to exercise-induced stress. Forty-three obese, AfricanAmerican subjects with hypertension were treated with nebivolol (5-10 mg/day) for 8 weeks. Before treatment the subjects underwent an exercise treadmill study to a level of eight metabolic equivalents. Circulating levels of soluble interleukin-6 (sIL-6), vascular cell adhesion molecule (VCAM-1), adiponectin and leptin were measured at pre-treadmill, and 1 min, 30 min, 60 min and 24 h after treadmill. After the 8-week treatment period, exercise treadmill study and the measurement of markers were repeated. Treatment with nebivolol reduced levels of sVCAM-1 at pre-exercise by 21% and at 1 and 30 min by 12.5 and 20%, respectively (Po0.005 from corresponding time point). In nebivolol-treated patients there was a reduction in sIL-6 levels by 20% and preexercise and at 1 and 60 min by 19.7 and 33.5%, respectively (Po0.005 from corresponding time point). Treatment with nebivolol increased levels of serum adiponectin by 28% (P ¼ 0.012) and decreased levels of leptin by 32% (Po0.005 from pre-treatment). Treatment with nebivolol improves markers of inflammation and obesity in a high-risk African-American population. Moreover, this effect is potentiated in response to exercise-induced stress. These results suggest that nebivolol differentially regulates markers of inflammation and obesity, thereby providing vascular protection.

The effects of angiotensin receptor blockers vs. calcium channel blockers on the acute exercise-induced inflammatory and thrombotic response

“…25 Similar favorable effects on vascular markers of inflammation have lately been reported for nebivolol in obese hypertensive patients exposed to exercise-induced stress. 22 The choice of the non-dihydropyridine diltiazem as a representative CCB in this study was based primarily on the fact that the antiinflammatory effects of this CCB have not been previously studied. Moreover, patients who are treated with dihydropyridines have a high prevalence of peripheral edema in countries with warmer climates, such as Greece, whereas those treated with verapamil have a higher prevalence of constipation.…”

“…12,14,16 Antihypertensive treatment has been associated with beneficial effects on subclinical inflammation and thrombosis at rest and during exercise. [22][23][24][25][26] Nevertheless, comparative studies between different BPlowering agents have not been previously reported.…”

Nebivolol Attenuates Neutrophil Lymphocyte Ratio: A Marker of Subclinical Inflammation in Hypertensive Patients

“…Apart from their beneficial effects on blood pressure, nebivolol has a very strong anti-inflammatory and antioxidant potential. Nebivolol reduces the level of various oxidative and inflammatory markers like oxidized LDL, 8-isoprostanes, CRP, interleukin- (IL-) 6, adiponectin, leptin, intercellular adhesions molecule (ICAM-1), vascular cell adhesions molecule (VCAM-1), and tumor necrosis factor- α in various clinical studies [ 12 , 13 ]. However lab detection of these markers is costly and usually not performed on routine clinical setting.…”

Effects of Resveratrol and Nebivolol on Isolated Vascular and Cardiac Tissues from Young Rats

“…Resveratrol and nebivolol have been demonstrated in both animal and human based studies to increase the bio-availability of nitric oxide [2, 4–6]. These two compounds have also been shown to exhibit beneficial effects on myocardial function by preventing hypertrophy [7, 8] as well as acting to decrease inflammation [9, 10] and oxidative stress [11, 12]. …”